H

HLB Life Science Co Ltd
KOSDAQ:067630

Watchlist Manager
HLB Life Science Co Ltd
KOSDAQ:067630
Watchlist
Price: 4 850 KRW 12.79%
Market Cap: ₩591.3B

HLB Life Science Co Ltd
Other

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

HLB Life Science Co Ltd
Other Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other CAGR 3Y CAGR 5Y CAGR 10Y
H
HLB Life Science Co Ltd
KOSDAQ:067630
Other
-₩50.1B
CAGR 3-Years
N/A
CAGR 5-Years
-38%
CAGR 10-Years
N/A
C
Chorokbaem Healthcare Co Ltd
KRX:118000
Other
₩338.3m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
W
WSI Co Ltd
KOSDAQ:299170
Other
₩20m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
W
Wonik Co Ltd
KOSDAQ:032940
Other
₩11.5m
CAGR 3-Years
52%
CAGR 5-Years
-12%
CAGR 10-Years
32%
B
BlueMTec Co Ltd
KOSDAQ:439580
Other
₩113.4m
CAGR 3-Years
-76%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

HLB Life Science Co Ltd
Glance View

Market Cap
591.3B KRW
Industry
Health Care

HLB Life Sciences Co., Ltd. engages in the provision of energy saving services. The company is headquartered in Hwaseong, Gyeonggi-Do. The company went IPO on 2008-11-25. Along with subsidiaries, the Company operates its business through four segments. The Pharmaceutical Distribution segment is involved in the sale of pharmaceuticals and raw materials through SHINWHAADVANCE.CO.LTD. The Energy Business segment is engaged in energy service company (ESCO) business. The company is equipped with equipments, assets and technical personnel to engage in energy saving investment business. The Bio Development segment is engaged in the development of extracorporeal circulation type bio space, hepatocyte treatment agents and hemostatic agents. The main products include anticancer drugs such as Tegatrabetan and Seclidemstat. The Other Business segment is involved in the investment of small business start-ups and venture businesses, as well as manufacturing and sale of light emitting diode (LED) products.

Intrinsic Value
1 385.45 KRW
Overvaluation 71%
Intrinsic Value
Price
H

See Also

What is HLB Life Science Co Ltd's Other?
Other
-50.1B KRW

Based on the financial report for Sep 30, 2025, HLB Life Science Co Ltd's Other amounts to -50.1B KRW.

What is HLB Life Science Co Ltd's Other growth rate?
Other CAGR 5Y
-38%

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett